Vireo Growth (VREOF) Debt Ratio (2020 - 2026)

Vireo Growth (VREOF) posted Debt Ratio of 0.21 for Q1 2026, up 21.43% sequentially from 0.18 in Q4 2025, and down 5.37% YoY from 0.23 in Q1 2025.

Vireo Growth (VREOF) Debt Ratio (2020 - 2026) Analysis & Trends

Vireo Growth has reported Debt Ratio for 7 years, with the latest figure at 0.21 in Q1 2026.

Quarterly Debt Ratio fell 5.37% year-over-year to 0.21 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.21 (down 5.37% YoY) and the FY2025 annual result came in at 0.18, down 22.3% from the prior year.
Debt Ratio climbed to 0.21 in Q1 2026 per VREOF's latest filing, from 0.18 in the prior quarter.
Over five years, Debt Ratio peaked at 0.66 in Q4 2023 and troughed at 0.16 in Q2 2025.
A 5-year average of 0.3 and a median of 0.3 in 2024 frame the typical range for Debt Ratio.
The sharpest annual moves came in 2022 and 2024: Debt Ratio soared 143.58% in 2022, then tumbled 65.52% in 2024.
Over 5 years, Debt Ratio stood at 0.36 in 2022, then jumped by 80.25% to 0.66 in 2023, then sank by 65.52% to 0.23 in 2024, then retreated by 22.3% to 0.18 in 2025, then increased by 21.43% to 0.21 in 2026.
According to Business Quant data, Debt Ratio over the past three periods registered 0.21, 0.18, and 0.22 for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Debt Ratio (Qtr)
1	Haleon	43.60 Bn	42.64 Bn	-	-0.13
2	Teva Pharmaceutical Industries	43.01 Bn	39.36 Bn	2.15 Bn	0.42
3	Zoetis	31.41 Bn	29.73 Bn	1.05 Bn	0.60
4	Takeda Pharmaceutical	28.62 Bn	22.82 Bn	5.10 Bn	0.32
5	United Therapeutics	22.13 Bn	19.47 Bn	683.80 Mn	-
6	Viatris	18.76 Bn	17.88 Bn	1.46 Bn	0.38
7	Neurocrine Biosciences	15.61 Bn	15.22 Bn	935.80 Mn	-
8	Elanco Animal Health	12.04 Bn	11.51 Bn	798.00 Mn	0.29
9	Dr Reddys Laboratories	10.07 Bn	9.90 Bn	-	0.12
10	Vireo Growth	491.44 Mn	349.14 Mn	95.30 Mn	0.23

Download Data